Literature DB >> 23098654

Induction of microRNA-24 by HIF-1 protects against ischemic injury in rat cardiomyocytes.

D-F Li1, J Tian, X Guo, L-M Huang, Y Xu, C-C Wang, J-F Wang, A-J Ren, W-J Yuan, L Lin.   

Abstract

MicroRNAs are emerging as important regulators of cardiac function. This study investigated the role of microRNA-24 (miR-24) in ischemic cardiomyocytes, based on the observation that miR-24 expression was significantly enhanced in the ischemic myocardium of rats. Using primary cultured rat cardiomyocytes, cell injury was induced by ischemic conditions, and the cells were evaluated for changes in lactate dehydrogenase (LDH) release, cell viability, apoptosis and necrosis. The results showed that miR-24 was increased in myocytes exposed to ischemia. When miR-24 was further overexpressed in ischemic myocytes using the mimic RNA sequence, LDH release was reduced, cell viability was enhanced, and apoptosis and necrosis rates were both decreased. By contrast, a deficiency in miR-24 resulted in the largest LDH release, lowest cell viability and highest apoptosis and necrosis rates in normal and ischemic myocytes, with significant changes compared to that of non-transfected myocytes. Additionally, the mRNA and protein levels of the pro-apoptotic gene, BCL2L11, were down-regulated by miR-24 overexpression and up-regulated by miR-24 deficiency. The luciferase reporter assay confirmed BCL2L11 to be a target of miR-24. Overall, this study showed a protective role for miR-24 against myocardial ischemia by inhibiting BCL2L11, and may represent a potential novel treatment for ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23098654     DOI: 10.33549/physiolres.932270

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  15 in total

1.  CRISPR/Cas9 Edited Induced Pluripotent Stem Cell-Based Vascular Tissues to Model Aging and Disease-Dependent Impairment.

Authors:  Aylin Acun; Pinar Zorlutuna
Journal:  Tissue Eng Part A       Date:  2019-04-30       Impact factor: 3.845

Review 2.  Molecular tissue changes in early myocardial ischemia: from pathophysiology to the identification of new diagnostic markers.

Authors:  Aleksandra Aljakna; Tony Fracasso; Sara Sabatasso
Journal:  Int J Legal Med       Date:  2018-01-23       Impact factor: 2.686

Review 3.  Differential expression of microRNAs in ischemic heart disease.

Authors:  Minwoo A Song; Alexandra N Paradis; Maresha S Gay; John Shin; Lubo Zhang
Journal:  Drug Discov Today       Date:  2014-10-23       Impact factor: 7.851

Review 4.  MicroRNAs in myocardial infarction.

Authors:  Reinier A Boon; Stefanie Dimmeler
Journal:  Nat Rev Cardiol       Date:  2014-12-16       Impact factor: 32.419

Review 5.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

6.  Effects of microRNA-21 and microRNA-24 inhibitors on neuronal apoptosis in ischemic stroke.

Authors:  Wansheng Liu; Xiaosheng Chen; Yu Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

7.  Cardiomyocyte-specific role of miR-24 in promoting cell survival.

Authors:  Chuner Guo; Yangmei Deng; Jiandong Liu; Li Qian
Journal:  J Cell Mol Med       Date:  2014-10-29       Impact factor: 5.310

Review 8.  Comparative Analyses of MicroRNA Microarrays during Cardiogenesis: Functional Perspectives.

Authors:  Fernando Bonet; Francisco Hernandez-Torres; Franciso J Esteban; Amelia Aranega; Diego Franco
Journal:  Microarrays (Basel)       Date:  2013-04-03

Review 9.  MicroRNAs expression profiles in cardiovascular diseases.

Authors:  Elsa Bronze-da-Rocha
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

10.  MicroRNA-126a-5p enhances myocardial ischemia-reperfusion injury through suppressing Hspb8 expression.

Authors:  Bimei Jiang; Yanjuan Liu; Pengfei Liang; Yuanbin Li; Zhenguo Liu; Zhongyi Tong; Qinglan Lv; Meidong Liu; Xianzhong Xiao
Journal:  Oncotarget       Date:  2017-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.